Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Subscribe To Our Newsletter & Stay Updated